Antares Pharma, Inc. v. Gordon Silver Limited and Verity Pharmaceuticals Inc.

CourtDistrict Court, D. Delaware
DecidedOctober 28, 2025
Docket1:24-cv-00634
StatusUnknown

This text of Antares Pharma, Inc. v. Gordon Silver Limited and Verity Pharmaceuticals Inc. (Antares Pharma, Inc. v. Gordon Silver Limited and Verity Pharmaceuticals Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Antares Pharma, Inc. v. Gordon Silver Limited and Verity Pharmaceuticals Inc., (D. Del. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ANTARES PHARMA, INC., Plaintiff, Vv. Civil Action No. 24-634-GBW . GORDON SILVER LIMITED and VERITY PHARMACEUTICALS INC., Defendants.

eee John A. Sensing, Bindu A. Palapura, Nicole K. Pedi, Malisa C. Dang, POTTER ANDERSON & CORROON LLP, Wilmington, DE. Counsel for Plaintiff . Richard L. Renck, Brandon Harper, DUANE MORRIS LLP, Wilmington, DE. Counsel for Defendants

MEMORANDUM OPINION October 28, 2025 Wilmington, Delaware

LA, GREGORY B. WILLIAMS UNITED STATES DISTRICT JUDGE

This action involves the allegedly improper sale of oral testosterone products for testosterone replacement therapy in adult males. Now pending before the Court is Defendant Gordon Silver Limited (“Gordon”) and Defendant Verity Pharmaceuticals Inc.’s (“Verity”) (together, “Defendants”) Partial Motion to Dismiss (“Motion”) (D.I. 32), which has been fully briefed (D.1. 33; D.I. 46; D.I. 47). For the following reasons, the Court grants the Motion. I. BACKGROUND The following are allegations from the Complaint (D.I. 4) that are taken as true and construed in the light most favorable to Plaintiff Antares Pharma, Inc. (“Plaintiff’ or “Antares”) for the purpose of resolving Defendants’ Motion. “Antares is a specialty pharmaceutical company” and “owns exclusive rights in the registered United States trademark for the name ‘ANTARES PHARMA.” D.I. 4 {| 16,17. This trademark is “found on labels that Antares provided for” TLANDO. D.1 4 418. “TLANDO is an oral testosterone product for testosterone replacement therapy in adult males.” D.I. 4 § 19. Antares and Lipocine, Inc. (“Lipocine”) entered an agreement called the Transition Services Agreement (“TSA”). D.I. 4 § 22. Lipocine “assigned the TSA to [Gordon], an affiliate of [Verity].” D.I. 4 § 23 (quotations omitted). The TSA, thus, “granted Defendants a limited license to purchase inventory of TLANDO, including finished products that contain Antares’ trademarks, tradenames, logos, trade dress and NDC number (‘Purchased Finished Product’), and to use and sell such Purchased Finished Product before the expiration of the Sell-off Period defined in the TSA.” D.L 4 § 28. “Upon executing the TSA, Defendants ordered” various Purchased

Finished Products. D.I. 4 435. After expiration of the Sell-off period, Defendants sold various Purchased Finished Products. D.I. 4 50. II. PROCEDURAL HISTORY On May 28, 2024, Plaintiff filed its Complaint in this Court. D.I. 4 §§ 60-77. Therein, Plaintiff alleges that Gordon’s sale of the Purchased Finished Products after the Sell-off Period constitutes trademark infringement. D.I. 4 60-70. Plaintiff also alleges that Verity’s facilitation of these sales constitutes contributory trademark infringement. D.I. 4 4 70-77. Plaintiff also alleges various contract claims. D.I. 4 9 78-111. On June 25, 2024, Defendants filed their Motion, seeking dismissal of the trademark claims. D.I. 32. In particular, Defendants contend that Plaintiff fails to state its claims for trademark infringement and contributory trademark infringement because the first sale doctrine precludes Plaintiffs claims as a matter of law. D.I. 33. Plaintiff disagrees with Defendants’ application of the first sale doctrine. D.I. 46. I. LEGAL STANDARDS To state a claim on which relief can be granted, a complaint must contain “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). Such claim must plausibly suggest “facts sufficient to ‘draw the reasonable inference that the defendant is liable for the misconduct alleged.’” Doe v. Princeton Univ., 30 F.4th 335, 342 (3d Cir. 2022) (quoting Ashcroft v. Igbal, 556 U.S. 662, 678 (2009)) (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 557 (2007). “A claim is facially plausible ‘when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.’” Klotz v. Celentano Stadtmauer & Walentowicz LLP, 991 F.3d 458, 462 (3d Cir. 2021) (quoting Jgbal, 556 U.S. at 678). But the Court will “‘disregard legal conclusions and recitals of

the elements of a cause of action supported by mere conclusory statements.’” Princeton Univ., 30 F.4th at 342 (quoting Davis v. Wells Fargo, 824 F.3d 333, 341 (3d Cir. 2016)). In evaluating a motion to dismiss, ““[t]he issue is not whether a plaintiff will ultimately prevail but whether the claimant is entitled to offer evidence to support the claims.’” Pinnavaia v. Celotex Asbestos Settlement Tr., 271 F. Supp. 3d 705, 708 (D. Del. 2017) (quoting In re Burlington Coat Factory Sec. Litig. 114 F.3d 1410, 1420 (3d Cir. 1997)), aff'd, 2018 U.S. App. LEXIS 38873 (3d Cir. Apr. 6, 2018). Rule 12(b)(6) requires the Court to “accept all factual allegations in a complaint as true and take them in the light most favorable to Plaintiff.” Brady v. Media, No. 23- cv-1078-GBW, 2024 U.S. Dist. LEXIS 160991, at *4 (D. Del. Sep. 6, 2024). “A motion to dismiss ‘may be granted only if, accepting all well-pleaded allegations in the complaint as true, and viewing them in the light most favorable to plaintiff, plaintiff is not entitled to relief.’” McCrone v, Acme Markets, 561 F. App’x 169, 172 (3d Cir. 2014) (quoting Burlington Coat Factory, 114 F.3d at 1420). The “movant bears the burden of demonstrating that the complainant failed to state a claim upon which relief may be granted.” Abbott Diabetes Care, Inc. v. DexCom, Inc., No. 23- cv-239-K AJ, 2024 U.S. Dist. LEXIS 96985, at *4 (D. Del. May 31, 2024). IV. DISCUSSION As described above, Defendants contend that Plaintiff fails to state its claims for trademark infringement and contributory trademark infringement because the first sale doctrine precludes Plaintiff's claims as a matter of law. Defendants are correct. “The law of trademark protects trademark owners in the exclusive use of their marks when use by another would be likely to cause confusion.” Maya Swimwear, Corp. v. Maya Swimwear, LLC, 789 F. Supp. 2d 506, 513 (D. Del. 2011) (citations omitted). “A plaintiff proves trademark infringement by demonstrating that: (1) the mark is valid and legally protectable; (2) plaintiff owns

the mark; and (3) the defendant’s use of its mark to identify goods or services is likely to create confusion concerning the origin of the goods or services.” Jd. The “affirmative defense of the first sale doctrine . . . prevents a finding of liability when “a purchaser does no more than stock, display and resell a producer’s product under the producer’s trademark.” Jd. at 514 (quoting Beltronics USA, Inc. v. Midwest Inventory Distrib., LLC, 562 F.3d 1067, 1073 (10th Cir. 2009)); see Iberia Foods Corp. v. Romeo, 150 F.3d 298, 301 (3d Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Australian Gold, Inc. v. Hatfield
436 F.3d 1228 (Tenth Circuit, 2006)
Maya Swimwear, Corp. v. Maya Swimwear, LLC
789 F. Supp. 2d 506 (D. Delaware, 2011)
Karen McCrone v. Acme Markets
561 F. App'x 169 (Third Circuit, 2014)
ITT Industries, Inc. v. Wastecorp. Inc.
87 F. App'x 287 (Third Circuit, 2004)
Terry Klotz v. Celentano Stadtmauer and Wale
991 F.3d 458 (Third Circuit, 2021)
John Doe v. Princeton University
30 F.4th 335 (Third Circuit, 2022)
Davis v. Wells Fargo, U.S.
824 F.3d 333 (Third Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Antares Pharma, Inc. v. Gordon Silver Limited and Verity Pharmaceuticals Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/antares-pharma-inc-v-gordon-silver-limited-and-verity-pharmaceuticals-ded-2025.